

Cellecetricon receives breakthrough order from AstraZeneca

The Swedish biotech tools company Cellecetricon has received a breakthrough order from AstraZeneca R&D Mölndal. The order represents an important landmark for Cellecetricon's commercialization of its patented Dynaflow™ technology for aggressive productivity increase in the drug discovery process.

Cellecetricon was formed 2001 with an extensive patent portfolio. The company has been expanding steadily and rapidly from the start, growing from 2 to 25 employees today. Cellecetricon's first product, the Dynaflow™ Microchip, is a ground-breaking drug screening tool that can be used by pharmaceutical companies to perform drug discovery with high speed and accuracy. The Dynaflow™ Microchip is based on a revolutionary microfluidic concept offering higher-throughput screening for drugs targeting ion channels, which are instrumental for brain and heart disease therapy.

"The Dynaflow™ Microchip has substantially increased our throughput and reduced the amount of compound needed for testing," says Dr. Ingemar Jacobson, who is Associate Principal Scientist at AstraZeneca R&D in Mölndal, Sweden. "The Dynaflow™ technology is superior in most aspects when compared to other perfusion systems on the market."

Jakob Lindberg, CEO of Cellecetricon, is pleased with the successful commercial launch of the company's Dynaflow™ technology less than one year after the company's Series A financing round. He says that AstraZeneca's decision to invest in the technology, after being involved in several rounds of beta-testing, is both gratifying and proof that Dynaflow™ drug-screening technology will be adopted by others.

About Cellecetricon

Cellecetricon is a Swedish biotechnology tools company that develops microfabricated cell-based tools for the pharmaceutical and biotechnology industries. Cellecetricon works at the interface between microtechnology and biology inventing products that will allow productivity increases primarily in the drug discovery process. The company was formed 2001 based on an extensive and solid patent portfolio within different areas such as high-throughput electrophysiology, patch-clamp, microfluidics, microfabrication, and electroporation. Cellecetricon is currently owned by Investor Growth Capital, Innovationskapital, Karolinska Investment Fund together with employees and seed investors. For more information please visit www.cellecetricon.se

Contact Details:

Jakob Lindberg, CEO

Phone: + 46 - 70 - 569 5471

jakob.lindberg@cellecetricon.se

Susanne Orwar, Communications Manager

Phone: +46 – 31 – 760 35 15

susanne.orwar@cellecetricon.se